Enlivex Therapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Enlivex Therapeutics Ltd. reported a significant net income of $1.236 billion for 2025, primarily due to unrealized gains from its digital asset treasury, while advancing its Allocetra osteoarthritis therapy to Phase IIb.
NASDAQ
Enlivex Therapeutics details its 2024 financial results and strategic focus on advancing Allocetra, particularly in osteoarthritis, while seeking partnerships for sepsis program development.
NASDAQ
20-F: Enlivex Therapeutics Focuses on Inflammatory and Autoimmune Diseases, Reports Sepsis Trial Data
Enlivex Therapeutics shifts strategic focus to inflammatory and autoimmune indications, highlighting positive topline data from a Phase II sepsis trial and progress in osteoarthritis clinical programs.